anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Radiotherapy (RT) is a cornerstone of the glioblastoma (GBM) treatment. However, the resistance of tumour cells to radiation results in early recurrence. The mechanisms underlying GBM radioresistance remain unclear. Screening for differentially expressed genes (DEGs) related to radiation might be a potential solution to this problem.
METHOD: RT-associated DEGs were screened based on the RNA sequencing of 15 paired primary and recurrent GBMs. The mRNA and protein expression of candidate genes were validated in RNA sequencing of The Chinese Genome Atlas (CGGA) dataset and 18 cases of GBM samples. The relationship between the candidate gene and radiation was confirmed in irradiated GBM cells. The association of candidate gene with clinical characteristics and survival was investigated in the CGGA and TCGA dataset. Biological function and pathway analysis were explored by gene ontology analysis. The association of the candidate gene with radiosensitivity was verified using cell counting Kit-8, comet, and colony formation assays in vitro and subcutaneous tumour xenograft experiments in vivo.
RESULTS: Gelsolin (GSN) was selected for further study. GSN expression was significant elevated in recurrent GBM and up-regulated in irradiated GBM cell lines. High expression of GSN was enriched in malignant phenotype of glioma. Moreover, high expression of GSN was associated with poor prognosis. Further investigation demonstrated that GSN-knockdown (GSN-KD) combined with RT significantly inhibited cell proliferation and enhanced radiosensitivity in vivo and in vitro. Mechanistically, GSN-KD could lead to more serious DNA damage and promotes apoptosis after RT.
CONCLUSION: Radiation induced up-regulated of GSN. GSN-KD could enhance the radiosensitivity of GBM.
After an initial screening for the eligibility based on current physical activity and levels of loneliness, up to 40 eligible participants will be randomised into the experimental or control group. Participants in the intervention group will be offered a 12-week outdoor group walking and health education workshops intervention. Each session will be performed once weekly for up to 90 minutes per session. Participants in the control group will be asked to maintain their current level of physical activity. Baseline and immediate post-intervention assessments will include anthropometry (height, weight, BMI), assessment of the resting blood pressure, physical activity for a 7-day period using accelerometer, questionnaires to assess loneliness, social support, social networks, social contacts, anxiety and depression, and expected outcomes of, and barriers to, exercise. Focus groups with participants will be conducted at 4 weeks mid-point and post-intervention to assess how the intervention might be improved; focus group transcripts will be thematically analysed using a phenomenological approach.
Each pregnant woman in the control group will be administered the individual information form, State Anxiety Scale, and Surgical Fear Scale data collection tools two hours before the surgery and will be released to the routine care of the institution. After two hours, the State Anxiety Scale and Surgical Fear Scale will be administered again. 6 hours after the cesarean section, the woman's pain will be assessed with the VAS pain scale and 24 hours later, the postpartum comfort scale will be administered.
Half of the global population is susceptible to malarial infection, with over one million annual deaths occurring as a result of the disease. Plasmodium, the causative agent of malaria, contains a vital plastid-organelle homologous to the chloroplasts of plants, known as the apicoplast. It was determined in previous studies that allyl isothiocyanate (AITC) is able to inhibit plant growth in a variety of species through effects on photosynthetic function. The purpose of this experiment was thus to examine the antimalarial properties of mustard oil, a natural form of AITC used as cooking oil in developing countries.  A one-step fluorescence assay used for antimalarial drug screening was employed throughout the experiment; resulting in the discovery that a 2µg/mL solution of pure mustard oil is able to significantly reduce Plasmodium falciparum infection in human red blood cells. Results of an MTT assay and light microscopy indicate that mustard oil exhibits equivalent mammalian toxicity to the common antimalarial drug Doxycycline. AITC is currently sold as an antibiotic, where clinical studies indicate that oral administration results in 90% absorption and rapid urinary drug recovery.  With no organic solvent necessary, pure mustard oil (purchased from a local grocery) inhibits over 94%  of parasite growth. Thus, the necessary dose of 10mg has potential to be taken orally, a treatment costing one million times less than the next leading antimalarial. Mustard oil production already occurs in malaria-endemic regions;  including Brazil and India, making this cooking oil an inexpensive, accessible and effective alternative to current treatments.
Primary Hypothesis: Brexpiprazole treatment will be associated with dose-dependent reduction in resting pupil diameter as a reflection of LC NE neuron target engagement in a group of subjects with PTSD. Secondary Hypothesis: Brexpiprazole therapy will be associated with a dosedependent decrease in CAPS-5 scores Tertiary Hypothesis: The pre-post treatment change in resting pupil diameter will be statistically significantly correlated with the pre-post change in CAPS-5 score.

Subjects will be screened and will undergo pupil measures with rating scales on Visit 1. Subject must be free of all psychotropic medications for one week before Day 1 assessment, except that prior FLX treatment will require 4 weeks of abstinence, and MAOIs will require 2 weeks of abstinence. They will be randomized to study drug an issued six weeks of study medication on Day 1 to take home. A phone call will then occur for safety assessment and medication adherence at every week. They will present back to the study site on Day 42 and undergo pupil measures with rating scales. They will then undergo a one week washout period. On Day 49 they will then be given another study drug to take home with rating scales and pupil measures obtained that day. A phone call will then occur for safety assessment and medication adherence at every week. They will present back to the study site on Day 91 and undergo pupil measures with rating scales. They will then undergo a one week washout period. On Day 98 they will then be given another study drug to take home with rating scales and pupil measures obtained that day. A phone call will then occur for safety assessment and medication adherence at every week. They will present back to the study site on Day 140 and undergo pupil measures with rating scales. No more study medication will be provide on Day 140 and a final visit will be scheduled for on Day 147, one week later, for and end of study interview with labs and physical exam. At each visit, other than the final visit, subjects will complete the CAPS-5, MADRS, Insomnia Severity Index, and Clinician Assessment for Adverse Effects.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice.

IMPOYZ Cream was evaluated in two randomized, multicenter, prospective, vehicle-controlled clinical trials in subjects with moderate to severe plaque psoriasis. Subjects applied IMPOYZ Cream or vehicle cream twice daily for 14 days. A total of 354 subjects applied IMPOYZ Cream and 178 subjects applied vehicle.

The adverse reaction that occurred in at least 1% of subjects treated with IMPOYZ Cream and at a higher incidence than in subjects treated with vehicle cream was application site discoloration (2% versus 1%). 

Less common local adverse events occurring in < 1% of subjects treated with IMPOYZ Cream were application site atrophy, telangiectasia and rash.
A computer-implemented method determines a geometric feature of a section of a blood vessel in an operating region. An image of the section is provided. An adapted blood vessel model is provided via image processing for the section by adapting a blood vessel model, which describes the section as a flow channel with a wall delimiting the latter and with an axis of symmetry. A centerline of the section of the blood vessel is determined as a contiguous pixel line. A relative spatial position of the side of the wall is ascertained based on the centerline and the image provided. The geometric feature is derived from the adapted blood vessel model. The disclosure also relates to a method for determining the length of a contiguous pixel line in an image and a system for determining a geometric feature of a section of an object.
The present invention relates to food products, in particular, to food supplements of specific medical purpose. The task of the invention is to extend indication for food supplement and to improve its stability and effectiveness. The food supplement comprises, in g: 1. Bee honey 921-919, Natural larval food 29,5-30,5,@Liquid extract of bee glue (propolis) 49,5-50,5; or 2. Bee honey 941-939, Lyophilised larval food 9,75-10,25, Liquid extract of bee glue (propolis) 49,25-50,75. To prepare food supplement bee honey is heated in reactor up to 35 oC, natural or  lyophilised larval food is admixed and then liquid extract of bee glue is added in small portions. The mixture obtained is packed into bottles and kept at 5-18 oC. The food additive is used as immunostimulator for treating and preventing diseases.
Regulated cell death (RCD) pathways, such as pyroptosis, apoptosis, and necroptosis, are essential for maintaining the body's balance, defending against pathogens, and eliminating abnormal cells that could lead to diseases like cancer. Although these pathways operate through distinct mechanisms, recent genetic and pharmacological studies have shown that they can interact and influence each other. The concept of "PANoptosis" has emerged, highlighting the interplay between pyroptosis, apoptosis, and necroptosis, especially during cellular responses to infections. This article provides a concise overview of PANoptosis and its molecular mechanisms, exploring its implications in various diseases. The review focuses on the extensive interactions among different RCD pathways, emphasizing the role of PANoptosis in infections, cytokine storms, inflammatory diseases, and cancer. Understanding PANoptosis is crucial for developing novel treatments for conditions involving infections, sterile inflammations, and cancer.
Aqueous extracts obtained by treating anterior lobes of the hypophysis first with an organic solvent and then with an aqueous solvent, as described in Specification 291,018, [Class 81 (i)], or by directly extracting anterior lobes of the hypophysis from sheep with an aqueous solvent, are treated to obtain the active substances therefrom by addition of a low molecular alcohol up to a concentration of at least 70 per cent at pH 6 to 8 to obtain a precipitate which is then extracted with weakly alkaline water, and the extract so obtained again treated with alcohol of the same concentration to obtain a second precipitate which is dissolved in water or physiological salt solution, and the solution frozen and dried.  The product contains the active substance of the glands showing gonadotropic action, together with the synergistic factor, the thyreotropic substance and the substance promoting lactation. Specifications 295,680 and 323,474, [both in Class 81 (i)], also are referred to.  The Specification as open to inspection under Sect. 91 states that the whole hypophysis gland of sheep may be treated.  This subject-matter does not appear in the Specification as accepted.
Standard NPWT with use of V.A.C. Ulta device employed at 125mmHg continuous suction.
OBJECTIVE: There is a lack of trustworthy information about Functional Somatic Symptoms (FSS) on the internet. This means integrative bio-psycho-social explanations of FSS and related health advice are not readily available to the public. To explore and address this problem, we carried out the bodysymptoms project, with the aim to build a website which presents current widely accepted explanations for FSS and shows how different explanations are inter-connected.
METHODS: Bodysymptoms was set up as a research-in-action project with a diverse range of international stakeholder-participants, combining approaches from patient and public involvement in healthcare with participatory design. 7 participants with lived experience of multi-system functional symptoms took part in the project and measures of meaningful engagement throughout the project were rated highly. This manuscript describes the methodology by which the website was developed.
RESULTS: Through iterative cycles we determined the requirements for an interactive explanatory model and co-created a novel online health interactive resource with integrated actionable health advice. The target end user are young adults with persistent physical symptoms, maintained by functional mechanisms. The overall aim is to empower people at risk of developing functional disorders to seek better health outcomes. The website is intended to be used prior to or alongside engagement with healthcare.
CONCLUSION: Bringing lived experience and multi-disciplinary perspectives into dialogue through participatory design can harness the power of research to create immediate shared value. This project has resulted in a usable open access website, bodysymptoms.org, which provides education about FSS for patients, healthcare professionals and members of the public looking to understand FSS.
Patients randomised to the PDT treatment (Intervention Arm) will have two courses of PDT treatment in total (for each lung treated). Follow-up is the same as for Control Arm patients: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
Apatinib 500mg once daily makes an initial dose and 28 days made one treatment cycle. All patients took the drug continuously until disease progression, intolerable toxicities, and patient-requested withdrawal. Appropriate supportive care were given.
PURPOSE:To prevent breakage or thermal deterioration of a core material and to eliminate formation of multicores in the wax by melting the wax once on the surface of particles having 5mu-5mm particle size, then solidifying the melted wax thus to permeate the wax into the coated film or deep into the particles. CONSTITUTION:After dipping primary particles having 5mu-5mm particle size in a soln. contg. wax in an org. solvent for a certain time, the particles are taken out and dried in vacuum to prepare primary particles coated with wax 9. Then, the conglomerated primary particles 3 are disintegrated to obtain aggregate of single core particles having primary coated film 9 as intermediate capsule product 11, which is melted instantaneously and quenched in a melting and cooling chamber 13. As a result, the rough surface of the primary coated film 9 becomes sufficiently smooth, and final coated film 16 having a shape matching the shape of the surface layer of the particle is obtd.
OBJECTIVES: Despite the fact that fibromyalgia, a widespread disease of the musculoskeletal system, has no specific treatment, patients have shown improvement after pharmacological intervention. Pregabalin has demonstrated efficacy; however, its adverse effects may reduce treatment adherence. In this context, neuromodulatory techniques such as transcranial direct current stimulation (tDCS) may be employed as a complementary pain-relieving method. Consequently, the purpose of this study was to evaluate the effect of pregabalin and tDCS treatments on the behavioral and biomarker parameters of rats submitted to a fibromyalgia-like model.
METHODS: Forty adult male Wistar rats were divided into two groups: control and reserpine. Five days after the end of the administration of reserpine (1 mg/kg/3 days) to induce a fibromyalgia-like model, rats were randomly assigned to receive either vehicle or pregabalin (30 mg/kg) along with sham or active- tDCS treatments. The evaluated behavioral parameters included mechanical allodynia by von Frey test and anxiety-like behaviors by elevated plus-maze test (time spent in opened and closed arms, number of entries in opened and closed arms, protected head-dipping, unprotected head-dipping [NPHD], grooming, rearing, fecal boluses). The biomarker analysis (brain-derived neurotrophic factor [BDNF] and tumor necrosis factor-α [TNF-α]) was performed in brainstem and cerebral cortex and in serum.
RESULTS: tDCS reversed the reduction in the mechanical nociceptive threshold and the decrease in the serum BDNF levels induced by the model of fibromyalgia; however, there was no effect of pregabalin in the mechanical threshold. There were no effects of pregabalin or tDCS found in TNF-α levels. The pain model induced an increase in grooming time and a decrease in NPHD and rearing; while tDCS reversed the increase in grooming, pregabalin reversed the decrease in NPHD.
CONCLUSIONS: tDCS was more effective than pregabalin in controlling nociception and anxiety-like behavior in a rat model-like fibromyalgia. Considering the translational aspect, our findings suggest that tDCS could be a potential non-pharmacological treatment for fibromyalgia.
There is disclosed a method and system for generating retinal signal data. Calibration data corresponding to an individual may be received. A threshold impedance may be determined based on the calibration data. Retinal signal data corresponding to the individual may be received. The impedance of the circuit collecting the retinal signal data may be compared to the threshold impedance to determine whether the retinal signal data contains any artifacts. A portion of the retinal signal data corresponding to the artifacts may be removed from the retinal signal data.
Efferocytosis and metabolic reprogramming of macrophages play crucial roles in myocardial infarction (MI) repair. TREM2 has been proven to participate in phagocytosis and metabolism, but how it modulates myocardial infarction remains unclear. In this study, we showed that macrophage-specific TREM2 deficiency worsened cardiac function and impaired post-MI repair. Using RNA-seq, protein and molecular docking, and Targeted Metabolomics (LC-MS), our data demonstrated that macrophages expressing TREM2 exhibited decreased SLC25A53 transcription through the SYK-SMAD4 signaling pathway after efferocytosis, which impaired NAD+ transport into mitochondria, downregulated SLC25A53 thereby causing the breakpoint in the TCA cycle and subsequently increased itaconate production. In vitro experiments confirmed that itaconate secreted by TREM2+ macrophages inhibited cardiomyocyte apoptosis and promoted fibroblast proliferation. Conversely, overexpression of TREM2 in macrophages could improve cardiac function. In summary, our study reveals a novel role for macrophage-specific TREM2 in MI, connecting efferocytosis to immune metabolism during cardiac repair.
The duration of a session was approximately a half-hour. The course duration was 8 sessions. The preferred frequency was once a week, however, the schedule was flexibly adjusted for patients' convenience.
Iron metabolism and leptin are interconnected, and both link with obesity. In this cross-sectional study, we hypothesized that serum iron markers associate with leptin, with body mass index (BMI) acting as a mediator, confounder, and effect modifier in this relationship. We analyzed data from the National Health and Nutrition Examination Survey III, with a focus on serum iron markers and leptin. The relationship between serum iron markers and leptin was determined by multiple linear regression. The bootstrap method was used to investigate the mediating effect of BMI on this association. Among 3888 American adults, serum iron and transferrin saturation showed a negative association with leptin (log2-transformed) (β: -0.010, 95% confidence interval [CI], -0.013 to -0.006, P < .001; β: -0.006, 95% CI, -0.008 to -0.004, P < .001). Total iron-binding capacity was positively associated with the serum concentration of leptin (log2-transformed) (β: 0.002, 95% CI, 0-0.004, P = .0292). Sex, BMI, and body fat percentage significantly influenced these associations. Notably, the association between the iron markers and leptin diminished in individuals with a BMI ≥30 kg/m2. There was no observable relationship between leptin and serum ferritin concentrations. BMI mediated 4.81% of the serum iron-leptin association, with no mediation of body fat percentage. Our study identified a link between serum iron and leptin, with BMI as a mediating factor. In clinical settings, it is vital to understand how treatments targeting iron metabolism can directly impact serum leptin concentration and the subsequent physiological changes.
Inborn errors of immunity (IEI) or primary immune deficiencies (PIDD) are caused by variants in genes encoding for molecules that are relevant to the innate or adaptive immune response. To date, defects in more than 450 different genes have been identified as causes of IEI, causing a constellation of heterogeneous clinical manifestations ranging from increased susceptibility to infection, to autoimmunity or autoinflammation. IEI that are mainly characterized by autoinflammation are broadly classified according to the inflammatory pathway that they predominantly perturb. Among autoinflammatory IEI are those characterized by the transcriptional upregulation of type I interferon genes and are referred to as interferonopathies. Within the spectrum of interferonopathies, genetic defects that affect the proteasome have been described to cause autoinflammatory disease and represent a growing area of investigation. This review is focused on describing the clinical, genetic, and molecular aspects of IEI associated with mutations that affect the proteasome and how the study of these diseases has contributed to delineate therapeutic interventions.
The invention discloses a Chinese medical spray for treating furunculosis, sore and furuncle and hemorrhoid. The Chinese medical spray is prepared from the following traditional Chinese medicinal raw materials (by weight): 1-2 parts of clausena lansium parasite, 1-2 parts of honeysuckle flower, 1-2 parts of cottonrose hibiscus and 1-2 parts of cottonrose hibiscus parasite. A preparation method of the Chinese medical spray comprises the following steps: fetching the above medicines, adding 4-8 parts of water, distilling in a distiller, collecting 2-4 parts of a distillate, adding a preservative according to 0.08-0.1 wt% of the distillate, and sub-packaging by the use of a containing bottle with a spray device. The Chinese medical spray has effects of clearing heat, dewetting and relieve internal heat or fever. When the Chinese medical spray is used to spray affected parts, patients with furunculosis, sore and furuncle and hemorrhoid in 200 cases are cured. The Chinese medical spray has achieved good clinical effects, and effective rate reaches 100%. Adverse reaction in local parts or the whole body never occurs during the medication, and medication safety is prompted.